nodes	percent_of_prediction	percent_of_DWPC	metapath
Bicalutamide—CYP2C9—Leflunomide—systemic scleroderma	0.112	0.338	CbGbCtD
Bicalutamide—CYP2D6—Captopril—systemic scleroderma	0.0804	0.243	CbGbCtD
Bicalutamide—CYP2C19—Prednisone—systemic scleroderma	0.0666	0.201	CbGbCtD
Bicalutamide—CYP3A4—Mycophenolate mofetil—systemic scleroderma	0.0403	0.121	CbGbCtD
Bicalutamide—CYP3A4—Prednisone—systemic scleroderma	0.0322	0.0971	CbGbCtD
Bicalutamide—CYP2C9—cardial valve—systemic scleroderma	0.0177	0.638	CbGeAlD
Bicalutamide—AR—connective tissue—systemic scleroderma	0.00148	0.0532	CbGeAlD
Bicalutamide—AR—smooth muscle tissue—systemic scleroderma	0.00135	0.0487	CbGeAlD
Bicalutamide—AR—skin of body—systemic scleroderma	0.00133	0.0481	CbGeAlD
Bicalutamide—AR—digestive system—systemic scleroderma	0.00107	0.0384	CbGeAlD
Bicalutamide—AR—tendon—systemic scleroderma	0.00102	0.0366	CbGeAlD
Bicalutamide—CYP2C19—digestive system—systemic scleroderma	0.000989	0.0356	CbGeAlD
Bicalutamide—AR—lung—systemic scleroderma	0.000891	0.0321	CbGeAlD
Bicalutamide—CYP2C9—digestive system—systemic scleroderma	0.000766	0.0276	CbGeAlD
Bicalutamide—CYP3A4—digestive system—systemic scleroderma	0.000584	0.0211	CbGeAlD
Bicalutamide—CYP2D6—digestive system—systemic scleroderma	0.000575	0.0207	CbGeAlD
Bicalutamide—Dyspnoea—Mycophenolic acid—systemic scleroderma	0.000387	0.000603	CcSEcCtD
Bicalutamide—Somnolence—Mycophenolic acid—systemic scleroderma	0.000386	0.000602	CcSEcCtD
Bicalutamide—Shock—Lisinopril—systemic scleroderma	0.000384	0.0006	CcSEcCtD
Bicalutamide—Angioedema—Mycophenolate mofetil—systemic scleroderma	0.000383	0.000598	CcSEcCtD
Bicalutamide—Thrombocytopenia—Lisinopril—systemic scleroderma	0.000382	0.000597	CcSEcCtD
Bicalutamide—Dyspepsia—Mycophenolic acid—systemic scleroderma	0.000382	0.000596	CcSEcCtD
Bicalutamide—Neutropenia—Prednisone—systemic scleroderma	0.000381	0.000595	CcSEcCtD
Bicalutamide—Abdominal pain—Azathioprine—systemic scleroderma	0.000381	0.000594	CcSEcCtD
Bicalutamide—Body temperature increased—Azathioprine—systemic scleroderma	0.000381	0.000594	CcSEcCtD
Bicalutamide—Skin disorder—Lisinopril—systemic scleroderma	0.000379	0.000592	CcSEcCtD
Bicalutamide—Hyperhidrosis—Lisinopril—systemic scleroderma	0.000378	0.000589	CcSEcCtD
Bicalutamide—Diarrhoea—Captopril—systemic scleroderma	0.000377	0.000589	CcSEcCtD
Bicalutamide—Decreased appetite—Mycophenolic acid—systemic scleroderma	0.000377	0.000588	CcSEcCtD
Bicalutamide—Syncope—Mycophenolate mofetil—systemic scleroderma	0.000376	0.000587	CcSEcCtD
Bicalutamide—Erectile dysfunction—Prednisone—systemic scleroderma	0.000376	0.000586	CcSEcCtD
Bicalutamide—Feeling abnormal—Leflunomide—systemic scleroderma	0.000375	0.000585	CcSEcCtD
Bicalutamide—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	0.000374	0.000584	CcSEcCtD
Bicalutamide—Fatigue—Mycophenolic acid—systemic scleroderma	0.000374	0.000584	CcSEcCtD
Bicalutamide—Nausea—Mometasone—systemic scleroderma	0.000373	0.000582	CcSEcCtD
Bicalutamide—Anorexia—Lisinopril—systemic scleroderma	0.000372	0.000581	CcSEcCtD
Bicalutamide—Gastrointestinal pain—Leflunomide—systemic scleroderma	0.000372	0.00058	CcSEcCtD
Bicalutamide—Weight increased—Prednisone—systemic scleroderma	0.000371	0.000579	CcSEcCtD
Bicalutamide—Constipation—Mycophenolic acid—systemic scleroderma	0.000371	0.000579	CcSEcCtD
Bicalutamide—Pain—Mycophenolic acid—systemic scleroderma	0.000371	0.000579	CcSEcCtD
Bicalutamide—Weight decreased—Prednisone—systemic scleroderma	0.000369	0.000576	CcSEcCtD
Bicalutamide—Loss of consciousness—Mycophenolate mofetil—systemic scleroderma	0.000369	0.000575	CcSEcCtD
Bicalutamide—Hyperglycaemia—Prednisone—systemic scleroderma	0.000368	0.000574	CcSEcCtD
Bicalutamide—Cough—Mycophenolate mofetil—systemic scleroderma	0.000366	0.000571	CcSEcCtD
Bicalutamide—Dizziness—Captopril—systemic scleroderma	0.000365	0.000569	CcSEcCtD
Bicalutamide—Liver function test abnormal—Methotrexate—systemic scleroderma	0.000364	0.000568	CcSEcCtD
Bicalutamide—Depression—Prednisone—systemic scleroderma	0.000363	0.000566	CcSEcCtD
Bicalutamide—Hypertension—Mycophenolate mofetil—systemic scleroderma	0.000362	0.000565	CcSEcCtD
Bicalutamide—Urticaria—Leflunomide—systemic scleroderma	0.000361	0.000564	CcSEcCtD
Bicalutamide—Abdominal pain—Leflunomide—systemic scleroderma	0.000359	0.000561	CcSEcCtD
Bicalutamide—Body temperature increased—Leflunomide—systemic scleroderma	0.000359	0.000561	CcSEcCtD
Bicalutamide—Acute coronary syndrome—Prednisone—systemic scleroderma	0.000359	0.00056	CcSEcCtD
Bicalutamide—Feeling abnormal—Mycophenolic acid—systemic scleroderma	0.000357	0.000558	CcSEcCtD
Bicalutamide—Chest pain—Mycophenolate mofetil—systemic scleroderma	0.000357	0.000557	CcSEcCtD
Bicalutamide—Myalgia—Mycophenolate mofetil—systemic scleroderma	0.000357	0.000557	CcSEcCtD
Bicalutamide—Myocardial infarction—Prednisone—systemic scleroderma	0.000357	0.000556	CcSEcCtD
Bicalutamide—Neuropathy peripheral—Prednisone—systemic scleroderma	0.000357	0.000556	CcSEcCtD
Bicalutamide—Breast disorder—Methotrexate—systemic scleroderma	0.000356	0.000556	CcSEcCtD
Bicalutamide—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	0.000356	0.000555	CcSEcCtD
Bicalutamide—Anxiety—Mycophenolate mofetil—systemic scleroderma	0.000356	0.000555	CcSEcCtD
Bicalutamide—Hypersensitivity—Azathioprine—systemic scleroderma	0.000355	0.000553	CcSEcCtD
Bicalutamide—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.000355	0.000553	CcSEcCtD
Bicalutamide—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.000355	0.000553	CcSEcCtD
Bicalutamide—Insomnia—Lisinopril—systemic scleroderma	0.000353	0.000551	CcSEcCtD
Bicalutamide—Paraesthesia—Lisinopril—systemic scleroderma	0.000351	0.000547	CcSEcCtD
Bicalutamide—Vomiting—Captopril—systemic scleroderma	0.000351	0.000547	CcSEcCtD
Bicalutamide—Dry mouth—Mycophenolate mofetil—systemic scleroderma	0.000349	0.000545	CcSEcCtD
Bicalutamide—Dyspnoea—Lisinopril—systemic scleroderma	0.000348	0.000543	CcSEcCtD
Bicalutamide—Rash—Captopril—systemic scleroderma	0.000348	0.000543	CcSEcCtD
Bicalutamide—Dermatitis—Captopril—systemic scleroderma	0.000347	0.000542	CcSEcCtD
Bicalutamide—Somnolence—Lisinopril—systemic scleroderma	0.000347	0.000542	CcSEcCtD
Bicalutamide—Headache—Captopril—systemic scleroderma	0.000346	0.000539	CcSEcCtD
Bicalutamide—Confusional state—Mycophenolate mofetil—systemic scleroderma	0.000345	0.000539	CcSEcCtD
Bicalutamide—Dyspepsia—Lisinopril—systemic scleroderma	0.000344	0.000537	CcSEcCtD
Bicalutamide—Abdominal pain—Mycophenolic acid—systemic scleroderma	0.000343	0.000535	CcSEcCtD
Bicalutamide—Body temperature increased—Mycophenolic acid—systemic scleroderma	0.000343	0.000535	CcSEcCtD
Bicalutamide—Oedema—Mycophenolate mofetil—systemic scleroderma	0.000342	0.000534	CcSEcCtD
Bicalutamide—Asthma—Methotrexate—systemic scleroderma	0.000341	0.000532	CcSEcCtD
Bicalutamide—Infection—Mycophenolate mofetil—systemic scleroderma	0.00034	0.000531	CcSEcCtD
Bicalutamide—Decreased appetite—Lisinopril—systemic scleroderma	0.00034	0.00053	CcSEcCtD
Bicalutamide—Eosinophilia—Methotrexate—systemic scleroderma	0.000338	0.000527	CcSEcCtD
Bicalutamide—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.000337	0.000526	CcSEcCtD
Bicalutamide—Fatigue—Lisinopril—systemic scleroderma	0.000337	0.000526	CcSEcCtD
Bicalutamide—Shock—Mycophenolate mofetil—systemic scleroderma	0.000337	0.000525	CcSEcCtD
Bicalutamide—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	0.000336	0.000524	CcSEcCtD
Bicalutamide—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	0.000335	0.000523	CcSEcCtD
Bicalutamide—Hypersensitivity—Leflunomide—systemic scleroderma	0.000335	0.000523	CcSEcCtD
Bicalutamide—Pain—Lisinopril—systemic scleroderma	0.000334	0.000521	CcSEcCtD
Bicalutamide—Constipation—Lisinopril—systemic scleroderma	0.000334	0.000521	CcSEcCtD
Bicalutamide—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.000332	0.000519	CcSEcCtD
Bicalutamide—Bradycardia—Prednisone—systemic scleroderma	0.000332	0.000519	CcSEcCtD
Bicalutamide—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	0.000331	0.000516	CcSEcCtD
Bicalutamide—Diarrhoea—Azathioprine—systemic scleroderma	0.000329	0.000514	CcSEcCtD
Bicalutamide—Haemoglobin—Prednisone—systemic scleroderma	0.000328	0.000512	CcSEcCtD
Bicalutamide—Nausea—Captopril—systemic scleroderma	0.000328	0.000511	CcSEcCtD
Bicalutamide—Haemorrhage—Prednisone—systemic scleroderma	0.000327	0.00051	CcSEcCtD
Bicalutamide—Anorexia—Mycophenolate mofetil—systemic scleroderma	0.000326	0.000509	CcSEcCtD
Bicalutamide—Asthenia—Leflunomide—systemic scleroderma	0.000326	0.000509	CcSEcCtD
Bicalutamide—Feeling abnormal—Lisinopril—systemic scleroderma	0.000322	0.000502	CcSEcCtD
Bicalutamide—Pruritus—Leflunomide—systemic scleroderma	0.000322	0.000502	CcSEcCtD
Bicalutamide—Gastrointestinal pain—Lisinopril—systemic scleroderma	0.000319	0.000498	CcSEcCtD
Bicalutamide—Dysuria—Methotrexate—systemic scleroderma	0.000319	0.000498	CcSEcCtD
Bicalutamide—Neutropenia—Methotrexate—systemic scleroderma	0.000319	0.000498	CcSEcCtD
Bicalutamide—Dizziness—Azathioprine—systemic scleroderma	0.000318	0.000497	CcSEcCtD
Bicalutamide—Erectile dysfunction—Methotrexate—systemic scleroderma	0.000314	0.00049	CcSEcCtD
Bicalutamide—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	0.000312	0.000487	CcSEcCtD
Bicalutamide—Asthenia—Mycophenolic acid—systemic scleroderma	0.000311	0.000486	CcSEcCtD
Bicalutamide—Diarrhoea—Leflunomide—systemic scleroderma	0.000311	0.000485	CcSEcCtD
Bicalutamide—Urticaria—Lisinopril—systemic scleroderma	0.00031	0.000484	CcSEcCtD
Bicalutamide—Insomnia—Mycophenolate mofetil—systemic scleroderma	0.00031	0.000483	CcSEcCtD
Bicalutamide—Abdominal pain—Lisinopril—systemic scleroderma	0.000309	0.000482	CcSEcCtD
Bicalutamide—Body temperature increased—Lisinopril—systemic scleroderma	0.000309	0.000482	CcSEcCtD
Bicalutamide—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	0.000307	0.00048	CcSEcCtD
Bicalutamide—Pruritus—Mycophenolic acid—systemic scleroderma	0.000307	0.000479	CcSEcCtD
Bicalutamide—Vomiting—Azathioprine—systemic scleroderma	0.000306	0.000478	CcSEcCtD
Bicalutamide—Pneumonia—Methotrexate—systemic scleroderma	0.000306	0.000477	CcSEcCtD
Bicalutamide—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	0.000305	0.000476	CcSEcCtD
Bicalutamide—Somnolence—Mycophenolate mofetil—systemic scleroderma	0.000304	0.000475	CcSEcCtD
Bicalutamide—Rash—Azathioprine—systemic scleroderma	0.000303	0.000474	CcSEcCtD
Bicalutamide—Dermatitis—Azathioprine—systemic scleroderma	0.000303	0.000473	CcSEcCtD
Bicalutamide—Depression—Methotrexate—systemic scleroderma	0.000303	0.000473	CcSEcCtD
Bicalutamide—Headache—Azathioprine—systemic scleroderma	0.000302	0.000471	CcSEcCtD
Bicalutamide—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	0.000301	0.00047	CcSEcCtD
Bicalutamide—Dizziness—Leflunomide—systemic scleroderma	0.000301	0.000469	CcSEcCtD
Bicalutamide—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	0.000297	0.000464	CcSEcCtD
Bicalutamide—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.000297	0.000463	CcSEcCtD
Bicalutamide—Angiopathy—Prednisone—systemic scleroderma	0.000296	0.000462	CcSEcCtD
Bicalutamide—Conjunctivitis—Methotrexate—systemic scleroderma	0.000295	0.000461	CcSEcCtD
Bicalutamide—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.000295	0.000461	CcSEcCtD
Bicalutamide—Immune system disorder—Prednisone—systemic scleroderma	0.000295	0.00046	CcSEcCtD
Bicalutamide—Pain—Mycophenolate mofetil—systemic scleroderma	0.000293	0.000457	CcSEcCtD
Bicalutamide—Constipation—Mycophenolate mofetil—systemic scleroderma	0.000293	0.000457	CcSEcCtD
Bicalutamide—Arrhythmia—Prednisone—systemic scleroderma	0.000292	0.000455	CcSEcCtD
Bicalutamide—Sweating—Methotrexate—systemic scleroderma	0.000291	0.000455	CcSEcCtD
Bicalutamide—Haematuria—Methotrexate—systemic scleroderma	0.00029	0.000452	CcSEcCtD
Bicalutamide—Vomiting—Leflunomide—systemic scleroderma	0.000289	0.000451	CcSEcCtD
Bicalutamide—Alopecia—Prednisone—systemic scleroderma	0.000289	0.00045	CcSEcCtD
Bicalutamide—Hypersensitivity—Lisinopril—systemic scleroderma	0.000288	0.000449	CcSEcCtD
Bicalutamide—Hepatobiliary disease—Methotrexate—systemic scleroderma	0.000287	0.000449	CcSEcCtD
Bicalutamide—Dizziness—Mycophenolic acid—systemic scleroderma	0.000287	0.000448	CcSEcCtD
Bicalutamide—Epistaxis—Methotrexate—systemic scleroderma	0.000287	0.000447	CcSEcCtD
Bicalutamide—Rash—Leflunomide—systemic scleroderma	0.000287	0.000447	CcSEcCtD
Bicalutamide—Dermatitis—Leflunomide—systemic scleroderma	0.000286	0.000447	CcSEcCtD
Bicalutamide—Mental disorder—Prednisone—systemic scleroderma	0.000286	0.000446	CcSEcCtD
Bicalutamide—Nausea—Azathioprine—systemic scleroderma	0.000286	0.000446	CcSEcCtD
Bicalutamide—Headache—Leflunomide—systemic scleroderma	0.000285	0.000444	CcSEcCtD
Bicalutamide—Malnutrition—Prednisone—systemic scleroderma	0.000284	0.000444	CcSEcCtD
Bicalutamide—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	0.000282	0.00044	CcSEcCtD
Bicalutamide—Asthenia—Lisinopril—systemic scleroderma	0.00028	0.000437	CcSEcCtD
Bicalutamide—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	0.00028	0.000437	CcSEcCtD
Bicalutamide—Pruritus—Lisinopril—systemic scleroderma	0.000276	0.000431	CcSEcCtD
Bicalutamide—Vomiting—Mycophenolic acid—systemic scleroderma	0.000276	0.00043	CcSEcCtD
Bicalutamide—Haemoglobin—Methotrexate—systemic scleroderma	0.000274	0.000428	CcSEcCtD
Bicalutamide—Rash—Mycophenolic acid—systemic scleroderma	0.000273	0.000427	CcSEcCtD
Bicalutamide—Dermatitis—Mycophenolic acid—systemic scleroderma	0.000273	0.000426	CcSEcCtD
Bicalutamide—Haemorrhage—Methotrexate—systemic scleroderma	0.000273	0.000426	CcSEcCtD
Bicalutamide—Urticaria—Mycophenolate mofetil—systemic scleroderma	0.000272	0.000424	CcSEcCtD
Bicalutamide—Headache—Mycophenolic acid—systemic scleroderma	0.000272	0.000424	CcSEcCtD
Bicalutamide—Pharyngitis—Methotrexate—systemic scleroderma	0.000271	0.000423	CcSEcCtD
Bicalutamide—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	0.000271	0.000422	CcSEcCtD
Bicalutamide—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	0.000271	0.000422	CcSEcCtD
Bicalutamide—Nausea—Leflunomide—systemic scleroderma	0.00027	0.000421	CcSEcCtD
Bicalutamide—Urinary tract disorder—Methotrexate—systemic scleroderma	0.000269	0.000421	CcSEcCtD
Bicalutamide—Urethral disorder—Methotrexate—systemic scleroderma	0.000267	0.000417	CcSEcCtD
Bicalutamide—Diarrhoea—Lisinopril—systemic scleroderma	0.000267	0.000417	CcSEcCtD
Bicalutamide—Visual impairment—Methotrexate—systemic scleroderma	0.000263	0.00041	CcSEcCtD
Bicalutamide—Anaemia—Prednisone—systemic scleroderma	0.000263	0.00041	CcSEcCtD
Bicalutamide—Angioedema—Prednisone—systemic scleroderma	0.00026	0.000405	CcSEcCtD
Bicalutamide—Dizziness—Lisinopril—systemic scleroderma	0.000258	0.000403	CcSEcCtD
Bicalutamide—Nausea—Mycophenolic acid—systemic scleroderma	0.000258	0.000402	CcSEcCtD
Bicalutamide—Syncope—Prednisone—systemic scleroderma	0.000255	0.000398	CcSEcCtD
Bicalutamide—Cardiac disorder—Methotrexate—systemic scleroderma	0.000253	0.000395	CcSEcCtD
Bicalutamide—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	0.000252	0.000394	CcSEcCtD
Bicalutamide—Loss of consciousness—Prednisone—systemic scleroderma	0.00025	0.00039	CcSEcCtD
Bicalutamide—Vomiting—Lisinopril—systemic scleroderma	0.000248	0.000388	CcSEcCtD
Bicalutamide—Angiopathy—Methotrexate—systemic scleroderma	0.000248	0.000386	CcSEcCtD
Bicalutamide—Immune system disorder—Methotrexate—systemic scleroderma	0.000246	0.000385	CcSEcCtD
Bicalutamide—Rash—Lisinopril—systemic scleroderma	0.000246	0.000384	CcSEcCtD
Bicalutamide—Dermatitis—Lisinopril—systemic scleroderma	0.000246	0.000384	CcSEcCtD
Bicalutamide—Mediastinal disorder—Methotrexate—systemic scleroderma	0.000246	0.000384	CcSEcCtD
Bicalutamide—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.000246	0.000383	CcSEcCtD
Bicalutamide—Hypertension—Prednisone—systemic scleroderma	0.000245	0.000383	CcSEcCtD
Bicalutamide—Chills—Methotrexate—systemic scleroderma	0.000245	0.000382	CcSEcCtD
Bicalutamide—Headache—Lisinopril—systemic scleroderma	0.000245	0.000382	CcSEcCtD
Bicalutamide—Pruritus—Mycophenolate mofetil—systemic scleroderma	0.000242	0.000378	CcSEcCtD
Bicalutamide—Myalgia—Prednisone—systemic scleroderma	0.000242	0.000378	CcSEcCtD
Bicalutamide—Anxiety—Prednisone—systemic scleroderma	0.000241	0.000376	CcSEcCtD
Bicalutamide—Alopecia—Methotrexate—systemic scleroderma	0.000241	0.000376	CcSEcCtD
Bicalutamide—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	0.00024	0.000375	CcSEcCtD
Bicalutamide—Mental disorder—Methotrexate—systemic scleroderma	0.000239	0.000373	CcSEcCtD
Bicalutamide—Malnutrition—Methotrexate—systemic scleroderma	0.000238	0.000371	CcSEcCtD
Bicalutamide—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	0.000234	0.000365	CcSEcCtD
Bicalutamide—Nausea—Lisinopril—systemic scleroderma	0.000232	0.000362	CcSEcCtD
Bicalutamide—Oedema—Prednisone—systemic scleroderma	0.000232	0.000362	CcSEcCtD
Bicalutamide—Infection—Prednisone—systemic scleroderma	0.00023	0.00036	CcSEcCtD
Bicalutamide—Back pain—Methotrexate—systemic scleroderma	0.00023	0.000359	CcSEcCtD
Bicalutamide—Shock—Prednisone—systemic scleroderma	0.000228	0.000356	CcSEcCtD
Bicalutamide—Nervous system disorder—Prednisone—systemic scleroderma	0.000227	0.000355	CcSEcCtD
Bicalutamide—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.000226	0.000353	CcSEcCtD
Bicalutamide—Skin disorder—Prednisone—systemic scleroderma	0.000225	0.000352	CcSEcCtD
Bicalutamide—Hyperhidrosis—Prednisone—systemic scleroderma	0.000224	0.00035	CcSEcCtD
Bicalutamide—Anorexia—Prednisone—systemic scleroderma	0.000221	0.000345	CcSEcCtD
Bicalutamide—Anaemia—Methotrexate—systemic scleroderma	0.00022	0.000343	CcSEcCtD
Bicalutamide—Vomiting—Mycophenolate mofetil—systemic scleroderma	0.000218	0.00034	CcSEcCtD
Bicalutamide—Rash—Mycophenolate mofetil—systemic scleroderma	0.000216	0.000337	CcSEcCtD
Bicalutamide—Dermatitis—Mycophenolate mofetil—systemic scleroderma	0.000216	0.000336	CcSEcCtD
Bicalutamide—Headache—Mycophenolate mofetil—systemic scleroderma	0.000214	0.000335	CcSEcCtD
Bicalutamide—Musculoskeletal discomfort—Prednisone—systemic scleroderma	0.000211	0.00033	CcSEcCtD
Bicalutamide—Insomnia—Prednisone—systemic scleroderma	0.00021	0.000327	CcSEcCtD
Bicalutamide—Paraesthesia—Prednisone—systemic scleroderma	0.000208	0.000325	CcSEcCtD
Bicalutamide—Cough—Methotrexate—systemic scleroderma	0.000207	0.000324	CcSEcCtD
Bicalutamide—Dyspepsia—Prednisone—systemic scleroderma	0.000204	0.000319	CcSEcCtD
Bicalutamide—Nausea—Mycophenolate mofetil—systemic scleroderma	0.000203	0.000317	CcSEcCtD
Bicalutamide—Chest pain—Methotrexate—systemic scleroderma	0.000202	0.000316	CcSEcCtD
Bicalutamide—Myalgia—Methotrexate—systemic scleroderma	0.000202	0.000316	CcSEcCtD
Bicalutamide—Decreased appetite—Prednisone—systemic scleroderma	0.000202	0.000315	CcSEcCtD
Bicalutamide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	0.000201	0.000313	CcSEcCtD
Bicalutamide—Fatigue—Prednisone—systemic scleroderma	0.0002	0.000312	CcSEcCtD
Bicalutamide—Constipation—Prednisone—systemic scleroderma	0.000198	0.00031	CcSEcCtD
Bicalutamide—Confusional state—Methotrexate—systemic scleroderma	0.000195	0.000305	CcSEcCtD
Bicalutamide—Infection—Methotrexate—systemic scleroderma	0.000193	0.000301	CcSEcCtD
Bicalutamide—Feeling abnormal—Prednisone—systemic scleroderma	0.000191	0.000298	CcSEcCtD
Bicalutamide—Nervous system disorder—Methotrexate—systemic scleroderma	0.00019	0.000297	CcSEcCtD
Bicalutamide—Thrombocytopenia—Methotrexate—systemic scleroderma	0.00019	0.000296	CcSEcCtD
Bicalutamide—Gastrointestinal pain—Prednisone—systemic scleroderma	0.00019	0.000296	CcSEcCtD
Bicalutamide—Skin disorder—Methotrexate—systemic scleroderma	0.000188	0.000294	CcSEcCtD
Bicalutamide—Hyperhidrosis—Methotrexate—systemic scleroderma	0.000187	0.000293	CcSEcCtD
Bicalutamide—Anorexia—Methotrexate—systemic scleroderma	0.000185	0.000288	CcSEcCtD
Bicalutamide—Urticaria—Prednisone—systemic scleroderma	0.000184	0.000288	CcSEcCtD
Bicalutamide—Body temperature increased—Prednisone—systemic scleroderma	0.000183	0.000286	CcSEcCtD
Bicalutamide—Abdominal pain—Prednisone—systemic scleroderma	0.000183	0.000286	CcSEcCtD
Bicalutamide—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	0.000177	0.000276	CcSEcCtD
Bicalutamide—Insomnia—Methotrexate—systemic scleroderma	0.000175	0.000274	CcSEcCtD
Bicalutamide—Paraesthesia—Methotrexate—systemic scleroderma	0.000174	0.000272	CcSEcCtD
Bicalutamide—Dyspnoea—Methotrexate—systemic scleroderma	0.000173	0.00027	CcSEcCtD
Bicalutamide—Somnolence—Methotrexate—systemic scleroderma	0.000172	0.000269	CcSEcCtD
Bicalutamide—Hypersensitivity—Prednisone—systemic scleroderma	0.000171	0.000267	CcSEcCtD
Bicalutamide—Dyspepsia—Methotrexate—systemic scleroderma	0.000171	0.000266	CcSEcCtD
Bicalutamide—Decreased appetite—Methotrexate—systemic scleroderma	0.000169	0.000263	CcSEcCtD
Bicalutamide—Gastrointestinal disorder—Methotrexate—systemic scleroderma	0.000167	0.000261	CcSEcCtD
Bicalutamide—Fatigue—Methotrexate—systemic scleroderma	0.000167	0.000261	CcSEcCtD
Bicalutamide—Asthenia—Prednisone—systemic scleroderma	0.000166	0.00026	CcSEcCtD
Bicalutamide—Pain—Methotrexate—systemic scleroderma	0.000166	0.000259	CcSEcCtD
Bicalutamide—Pruritus—Prednisone—systemic scleroderma	0.000164	0.000256	CcSEcCtD
Bicalutamide—Feeling abnormal—Methotrexate—systemic scleroderma	0.00016	0.000249	CcSEcCtD
Bicalutamide—Diarrhoea—Prednisone—systemic scleroderma	0.000159	0.000248	CcSEcCtD
Bicalutamide—Gastrointestinal pain—Methotrexate—systemic scleroderma	0.000159	0.000247	CcSEcCtD
Bicalutamide—Urticaria—Methotrexate—systemic scleroderma	0.000154	0.00024	CcSEcCtD
Bicalutamide—Dizziness—Prednisone—systemic scleroderma	0.000153	0.000239	CcSEcCtD
Bicalutamide—Abdominal pain—Methotrexate—systemic scleroderma	0.000153	0.000239	CcSEcCtD
Bicalutamide—Body temperature increased—Methotrexate—systemic scleroderma	0.000153	0.000239	CcSEcCtD
Bicalutamide—Vomiting—Prednisone—systemic scleroderma	0.000147	0.00023	CcSEcCtD
Bicalutamide—Rash—Prednisone—systemic scleroderma	0.000146	0.000228	CcSEcCtD
Bicalutamide—Dermatitis—Prednisone—systemic scleroderma	0.000146	0.000228	CcSEcCtD
Bicalutamide—Headache—Prednisone—systemic scleroderma	0.000145	0.000227	CcSEcCtD
Bicalutamide—Hypersensitivity—Methotrexate—systemic scleroderma	0.000143	0.000223	CcSEcCtD
Bicalutamide—Asthenia—Methotrexate—systemic scleroderma	0.000139	0.000217	CcSEcCtD
Bicalutamide—Nausea—Prednisone—systemic scleroderma	0.000138	0.000215	CcSEcCtD
Bicalutamide—Pruritus—Methotrexate—systemic scleroderma	0.000137	0.000214	CcSEcCtD
Bicalutamide—Diarrhoea—Methotrexate—systemic scleroderma	0.000133	0.000207	CcSEcCtD
Bicalutamide—Dizziness—Methotrexate—systemic scleroderma	0.000128	0.0002	CcSEcCtD
Bicalutamide—Vomiting—Methotrexate—systemic scleroderma	0.000123	0.000192	CcSEcCtD
Bicalutamide—Rash—Methotrexate—systemic scleroderma	0.000122	0.000191	CcSEcCtD
Bicalutamide—Dermatitis—Methotrexate—systemic scleroderma	0.000122	0.000191	CcSEcCtD
Bicalutamide—Headache—Methotrexate—systemic scleroderma	0.000121	0.00019	CcSEcCtD
Bicalutamide—Nausea—Methotrexate—systemic scleroderma	0.000115	0.00018	CcSEcCtD
